Zosano Pharma Corporation, a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver therapeutics conveniently through the skin for the treatment of a variety of indications, today announced the election of Joseph "Jay" P. Hagan to its Board of Directors, effective May 22, 2015. Mr. Hagan is Executive Vice President, Chief Business & Financial Officer of Orexigen Therapeutics, Inc. (Nasdaq:OREX), a public biotechnology company focused on the treatment of obesity.
"We welcome Jay to the Zosano Board of Directors," said Bruce Steel, Chairman of the Board of Directors of Zosano Pharma. "Jay is a seasoned business and financial executive with a significant track record in complex partnerships and transactions who will add additional breadth of perspective to our Board as Zosano advances its clinical development programs in osteoporosis, hypoglycemia and migraine."
Mr. Hagan has served as Orexigen's Chief Business & Financial Officer since 2011. From May 2009 to June 2011, Mr. Hagan served as Orexigen's Senior Vice President, Corporate Development, Strategy and Communications. Prior to Orexigen, Mr. Hagan worked at Amgen, from September 1998 to April 2008, where he served in various senior business development roles, including founder and Managing Director of Amgen Ventures. Prior to starting the Amgen Ventures fund, Mr. Hagan was Head of Corporate Development at Amgen, leading such notable transactions as the acquisitions of Immunex and Tularik and the spinouts of Novantrone and Relypsa, as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego.
"I look forward to working with the Zosano Board of Directors and management team to maximize the value of the company and its programs," said Mr. Hagan. "It's exciting to join the Board at this stage given the breadth of potential applications to improve patients' lives with Zosano's novel therapeutic delivery technology."
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications. Zosano Pharma's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano Pharma's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.